TB PRACTECAL – PKPD sub-study

Project Summary

Drug-resistant tuberculosis is a major global health challenge, treatment remains difficult. TB-PRACETAL has been investigating three oral only drug combinations; pretomanide, linezolid and bedaquiline with or without moxifloxacin or clofazimine.

A pharmacokinetic-pharmacodynamic study was nested into TB-PRACTECAL in order to investigate the relationship between the patients’ antibiotic exposure and sterilizing effects and treatment outcome. With this information we can inform optimization of dosing regimens to treat drug-resistant tuberculosis.

Key Project Information

Dates: 1 January 2017 - 31st December 2022 

UCL IGH Lead: Frank Kloprogge 

Principal Investigator: Bern-Thomas Nyang'wa, Médecins Sans Frontières

Location: Belarus, South Africa, Uzbekistan

Funding: Médecins Sans Frontières

Contact: d.evangelopoulos@ucl.ac.uk

Research Team

Bern-Thomas Nyang'wa

Frank Kloprogge

Zhonghui Huang

Geraint Davies

David Moore

Publications

 Nyang'wa BT, Kloprogge F, Moore DAJ, Bustinduy A, Motta I, Berry C, Davies GR. Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial. BMJ Open. 2021 Sep 6;11(9):e047185